Works matching IS 20420188 AND DT 2024

Results: 37
    1
    2
    3
    4
    5
    6

    Comparing the efficacy and safety of weekly somatrogon with daily somatropin to treat children with growth hormone deficiency: a plain language summary of publication from that of daily somatropin injections to treat children who don't make enough growth hormone to grow adequately. ○ Efficacy refers to how well a drug works in a clinical trial. ○ Children treated with weekly somatrogon had an increased growth rate, similar to that of children treated with daily somatropin. • The safety of weekly somatrogon injections was similar to that of daily somatropin injections. The original scientific article on which this summary is based was published in The Journal of Clinical Endocrinology & Metabolism and can be accessed for free at:https://academic.oup.com/jcem/article/107/7/e2717/6566444. The details of the original article are as follows: Cheri L. Deal, Joel Steelman, Elpis Vlachopapadopoulou, Renata Stawerska, Lawrence A Silverman, Moshe Phillip, Ho-Seong Kim, CheolWoo Ko, Oleg Malievskiy, Jose F. Cara, Carl L. Roland, Carrie Turich Taylor, Srinivas Rao Valluri, Michael P. Wajnrajch, Aleksandra Pastrak, and Bradley S. Miller. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab 2022; 107(7): e2717–e2728. The purpose of this plain language summary is to help you to understand the findings from recent research. • Somatrogon is used to treat growth hormone deficiency (the condition under study that is discussed in this summary). Approval varies by country; please check with your local healthcare provider for more details. • The results of this study may differ from those of other studies. Physicians/providers should make treatment decisions based on all available evidence and not on the results of a single study.

    Published in:
    Therapeutic Advances in Endocrinology & Metabolism, 2024, p. 1, doi. 10.1177/20420188241277404
    By:
    • Deal, Cheri L.;
    • Steelman, Joel;
    • Vlachopapadopoulou, Elpis;
    • Stawerska, Renata;
    • Silverman, Lawrence A.;
    • Phillip, Moshe;
    • Kim, Ho-Seong;
    • Ko, CheolWoo;
    • Malievskiy, Oleg;
    • Cara, Jose F.;
    • Roland, Carl L.;
    • Taylor, Carrie Turich;
    • Valluri, Srinivas Rao;
    • Wajnrajch, Michael P.;
    • Pastrak, Aleksandra;
    • Miller, Bradley S.
    Publication type:
    Article
    7
    8

    Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study.

    Published in:
    Therapeutic Advances in Endocrinology & Metabolism, 2024, p. 1, doi. 10.1177/20420188241294134
    By:
    • Schindler, Christoph;
    • Mikosiński, Jacek;
    • Mikosiński, Pawel;
    • Kärkkäinen, Hanna-Riikka;
    • Sanio, Mirka;
    • Kurkipuro, Jere;
    • Mierau, Igor;
    • Smith, Wesley;
    • Vartiainen, Aki;
    • Décory, Laurent;
    • Weber, Dirk;
    • Wirth, Thomas;
    • Yrjänheikki, Juha;
    • Schellong, Sebastian;
    • Samaranayake, Haritha
    Publication type:
    Article
    9

    Understanding the burden of weekly somatrogon injections compared with daily somatropin injections in children with growth hormone deficiency: a plain language summary of publication somatrogon injections were less of a burden than once-daily somatropin injections. • The safety of weekly somatrogon was similar to that of daily somatropin. • Compared with daily somatropin injections, children with growth hormone deficiency may be less likely to miss weekly somatrogon injections. ○ This is because weekly somatrogon injections were less of a burden and were less likely to interfere with daily activities compared with daily somatropin injections. The purpose of this plain language summary is to help you to understand the findings from recent research. • Somatrogon is used to treat the condition under study that is discussed in this summary. Approval varies by country; please check with your local provider for more details. • The results of this study may differ from those of other studies. Health professionals should make treatment decisions based on all available evidence and not on the results of a single study. This original scientific article on which this summary is based was published in the Journal of the Endocrine Society and can be accessed for free at: https://academic.oup.com/jes/article/6/10/bvac117/6695276. The details of the original article are as follows: Aristides K. Maniatis, Mauri Carakushansky, Sonya Galcheva, Gnanagurudasan Prakasam, Larry A. Fox, Adriana Dankovcikova, Jane Loftus, Andrew A. Palladino, Maria de los Angeles Resa, Carrie Turich Taylor, Mehul T. Dattani, Jan Lebl. Treatment burden of weekly somatrogon versus daily somatropin in children with growth hormone deficiency: a randomized study. J Endocr Soc 2022; 6(10): bvac117. DOI: 10.1210/jendso/bvac117.

    Published in:
    Therapeutic Advances in Endocrinology & Metabolism, 2024, p. 1, doi. 10.1177/20420188241274363
    By:
    • Maniatis, Aristides K.;
    • Carakushansky, Mauri;
    • Galcheva, Sonya;
    • Prakasam, Gnanagurudasan;
    • Fox, Larry A.;
    • Dankovcikova, Adriana;
    • Loftus, Jane;
    • Palladino, Andrew A.;
    • Resa, Maria de los Angeles;
    • Taylor, Carrie Turich;
    • Dattani, Mehul T.;
    • Lebl, Jan
    Publication type:
    Article
    10

    Comparing quality of life in traditional face-to-face visits with a hybrid approach of telemedicine with in-person follow-ups in recent users of advanced closed-loop systems: a randomized controlled clinical trial in patients with type 1 diabetes.

    Published in:
    Therapeutic Advances in Endocrinology & Metabolism, 2024, p. 1, doi. 10.1177/20420188241288789
    By:
    • Nattero-Chávez, Lía;
    • de La Calle, Esther;
    • Lecumberri-Pascual, Edurne;
    • Bayona Cebada, Ane;
    • Ruiz Gracia, Teresa;
    • Quintero Tobar, Alejandra;
    • Lorenzo Moñino, Mar;
    • Sánchez Rodríguez, Cristina;
    • Izquierdo, Ana;
    • Escobar-Morreale, Héctor F.;
    • Luque-Ramírez, Manuel
    Publication type:
    Article
    11
    12
    13

    Growth hormone treatment in children with Prader–Willi syndrome: safety and effectiveness data from the PATRO Children study.

    Published in:
    Therapeutic Advances in Endocrinology & Metabolism, 2024, p. 1, doi. 10.1177/20420188241264343
    By:
    • Lämmer, Constanze;
    • Backeljauw, Philippe;
    • Tauber, Maite;
    • Kanumakala, Shankar;
    • Loche, Sandro;
    • Otfried Schwab, Karl;
    • Pfäffle, Roland;
    • Höybye, Charlotte;
    • Lundberg, Elena;
    • Dahlgren, Jovanna;
    • Ek, Anna E.;
    • Battelino, Tadej;
    • Kriström, Berit;
    • Esmael, Altaher;
    • Zabransky, Markus
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37